How do you reconcile the different trial results of KEYNOTE 574 and IMmotion010 for adjuvant checkpoint inhibitor use in RCC?
Do the negative results of IMmotion010 give you pause to offer pembrolizumab or change to which patients you offer adjuvant pembrolizumab?